Next Article in Journal
HIV Capsid Inhibitors Beyond PF74
Previous Article in Journal
Pathology is Always Around Us: Apophenia in Pathology, a Remarkable Unreported Phenomenon
Previous Article in Special Issue
Mechanism of Fibrosis Induced by Echinococcus spp.
Open AccessFeature PaperCase Report

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab

by An-Yu Chen 1 and Helieh S. Oz 2,*
1
Gastroenterology, Lexington Clinic, Lexington, KY 40504, USA, [email protected]
2
Department of Medicine, UK Medical Center, Lexington, KY 40536, USA
*
Author to whom correspondence should be addressed.
Diseases 2019, 7(4), 55; https://doi.org/10.3390/diseases7040055
Received: 21 August 2019 / Revised: 25 September 2019 / Accepted: 26 September 2019 / Published: 28 September 2019
(This article belongs to the Special Issue Chronic Inflammatory and Infectious Diseases)
Ulcerative colitis is a chronic debilitating disease characterized by relapsing in intestinal inflammation and ulcers with no available cure. This is a clinical case report of a 52-year-old female patient with 30 years history of left-sided chronic ulcerative colitis controlled with standard of care (mesalamine and azathioprine) which subsequently relapsed and developed into active refractory ulcerative colitis. The patient became unresponsive to her medications including different forms of mesalamines and did not respond favorably to any of the other current therapies. Numerous attempts to stabilize her condition with immunosuppressants, steroids, probiotics, antibiotics, mesalamines, and various biologic agents failed to improve her clinical symptoms, and the patient was being considered for colectomy. As the last resort, modified therapy was prescribed with ustekinumab, a non-selective, anti-IL12/23 p40 monoclonal antibody. This medication has not been yet approved for use in ulcerative colitis patients. In this clinical case we report the efficacy of ustekinumab to rapidly induce and maintain remission of the severe chronic ulcerative colitis in the patient. To the best of our knowledge, this is the first report of utilizing ustakinamub therapy for rapid induction in an active refractory ulcerative colitis patient resulting in complete remission for over one year. View Full-Text
Keywords: inflammatory bowel disease; ulcerative colitis; biologics; ustekinumab; therapeutics inflammatory bowel disease; ulcerative colitis; biologics; ustekinumab; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Chen, A.-Y.; Oz, H.S. Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab. Diseases 2019, 7, 55.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop